AI-Reviewed Research, Clinical Excellence & Evidence-Based Practice in Aesthetic Medicine— Curated and reviewed by practising aesthetic clinicians
Regulatory updates, product alerts, peer-reviewed research highlights, and HSI announcements — filtered by region. Editorial commentary, not promotional.
The US Food and Drug Administration has updated its consumer and clinician alert on counterfeit Botox vials circulating outside the licit supply chain, following further confirmed adverse events including botulism-like symptoms requiring hospitalisation.
The American Society for Dermatologic Surgery has released a 2026 consensus statement on the recognition and stepwise management of intravascular filler events, reinforcing hyaluronidase dosing and ophthalmology referral thresholds.
The US Food and Drug Administration has declared decisive steps to restrict access to GLP-1 ingredients for non-FDA-approved compounded drugs, and on 30 April 2026 proposed removing semaglutide and tirzepatide from the 503B bulks list, citing stabilising branded supply.
The US Food and Drug Administration has approved Wegovy as the first once-daily oral GLP-1 weight-loss pill for chronic weight management in adults with obesity. Developed by Novo Nordisk, the tablet contains semaglutide and became available in US pharmacies from January 2026.
Industry news is curated by the HSI editorial board. Items summarise external regulatory, product, and peer-reviewed developments and link to primary sources. They do not constitute clinical guidance. For peer-reviewed analysis, see the main journal.